Literature DB >> 12131080

Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment.

Charles E Binkley1, Sandro Cinti, Diane M Simeone, Lisa M Colletti.   

Abstract

OBJECTIVE: To familiarize surgeons with the specific complications of cutaneous, gastrointestinal, inhalation, and systemic infection with Bacillus Anthracis, which may require surgical treatment. SUMMARY BACKGROUND DATA: The recent cases of intentional exposure to Bacillus Anthracis in the United States make familiarity with the basic microbiology, clinical manifestations, diagnosis, treatment, and control of this disease essential if mortality and morbidity is to be minimized, particularly following mass exposure. Although the treatment of Bacillus Anthracis infection is primarily medical, there are specific surgical complications with which the surgeon should be familiar.
METHODS: A review of the literature was undertaken, utilizing electronic databases on infection with Bacillus Anthracis, as well as consultation with experts in this field. Emphasis was placed on the diagnosis and treatment of complications of infection that might require surgical intervention.
RESULTS: Cutaneous anthrax infection results in eschar formation and massive soft tissue edema. When involving the extremities, increased compartment pressure requiring fasciotomy may result. Primary infection of the gastrointestinal tract may result in oropharyngeal edema and respiratory compromise requiring a surgical airway. Direct involvement of the lower gastrointestinal tract can result in intestinal ulceration, necrosis, bleeding, and perforation, which would require surgical exploration and resection of affected segments. Systemic sepsis, most often associated with inhalation anthrax, can cause massive ascites, electrolyte derangements, and profound shock requiring aggressive fluid resuscitation and careful hemodynamic monitoring and respiratory support. Systemic anthrax infection can also lead to gastrointestinal involvement by hematogenous dissemination, resulting in complications and requiring surgical management similar to direct gastrointestinal infection.
CONCLUSIONS: Cutaneous, gastrointestinal, inhalation and systemic infection with Bacillus Anthracis can result in complications which would require familiarity with the pathogenesis and manifestations of this disease in order to recognize and treat promptly and successfully by surgical intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12131080      PMCID: PMC1422543          DOI: 10.1097/00000658-200207000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  80 in total

1.  Polyglutamic acid from Bacillus anthracis grown in vivo; structure and aggressin activity.

Authors:  H T ZWARTOUW; H SMITH
Journal:  Biochem J       Date:  1956-07       Impact factor: 3.857

Review 2.  The monitoring and detection of Bacillus anthracis in the environment.

Authors:  R W Titball; P C Turnbull; R A Hutson
Journal:  Soc Appl Bacteriol Symp Ser       Date:  1991

3.  Leads from the MMWR. Human cutaneous anthrax--North Carolina, 1987.

Authors: 
Journal:  JAMA       Date:  1988-08-05       Impact factor: 56.272

4.  Survival of a patient with intestinal anthrax.

Authors:  D R Nalin; B Sultana; R Sahunja; A K Islam; M A Rahim; M Islam; B S Costa; N Mawla; W B Greenough
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

5.  Bacillus anthracis as a cause of bacterial meningitis.

Authors:  P Tabatabaie; A Syadati
Journal:  Pediatr Infect Dis J       Date:  1993-12       Impact factor: 2.129

6.  Penicillin therapy of human cutaneous anthrax.

Authors:  H A Ronaghy; B Azadeh; E Kohout; W Dutz
Journal:  Curr Ther Res Clin Exp       Date:  1972-11

7.  Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay.

Authors:  L H Harrison; J W Ezzell; T G Abshire; S Kidd; A F Kaufmann
Journal:  J Infect Dis       Date:  1989-10       Impact factor: 5.226

8.  Construction and characterization of a protective antigen-deficient Bacillus anthracis strain.

Authors:  A Cataldi; E Labruyère; M Mock
Journal:  Mol Microbiol       Date:  1990-07       Impact factor: 3.501

9.  A case of cutaneous anthrax with toxaemic shock.

Authors:  M Doğanay; M Bakir; I Dökmetaş
Journal:  Br J Dermatol       Date:  1987-11       Impact factor: 9.302

10.  Outbreak of oral-oropharyngeal anthrax: an unusual manifestation of human infection with Bacillus anthracis.

Authors:  T Sirisanthana; N Navachareon; P Tharavichitkul; V Sirisanthana; A E Brown
Journal:  Am J Trop Med Hyg       Date:  1984-01       Impact factor: 2.345

View more
  5 in total

1.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

2.  Ionic Cross-linked Chitosan Beads for Extended Release of Ciprofloxacin: In vitro Characterization.

Authors:  A Srinatha; J K Pandit; S Singh
Journal:  Indian J Pharm Sci       Date:  2008-01       Impact factor: 0.975

3.  Label-Free Detection and Discrimination of Bacterial Pathogens Based on Hemin Recognition.

Authors:  Thora R Maltais; Avijit K Adak; Waleed Younis; Mohamed N Seleem; Alexander Wei
Journal:  Bioconjug Chem       Date:  2016-07-01       Impact factor: 4.774

4.  Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Authors:  Katherine A Hendricks; Mary E Wright; Sean V Shadomy; John S Bradley; Meredith G Morrow; Andy T Pavia; Ethan Rubinstein; Jon-Erik C Holty; Nancy E Messonnier; Theresa L Smith; Nicki Pesik; Tracee A Treadwell; William A Bower
Journal:  Emerg Infect Dis       Date:  2014-02       Impact factor: 6.883

5.  Do low preoperative vitamin D levels reduce the accuracy of quick parathyroid hormone in predicting postthyroidectomy hypocalcemia?

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Benjamin J Cowling; Yuen Ki Fong; Desmond Kwan-Kit Chan; Grace Kin-Yee Hung
Journal:  Ann Surg Oncol       Date:  2012-09-12       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.